Methylation of PITX2 DNA feasible in prostate biopsies

December 13, 2016

(HealthDay)—For patients with prostate cancer (PCa), methylation of the paired-like homeodomain transcription factor 2 (PITX2) gene is feasible for individualized risk assessment in prostate core biopsies before surgery, according to a study published online Dec. 8 in the Journal of Molecular Diagnostics.

Barbara Uhl, from the University Hospital Bonn in Germany, and colleagues examined whether PITX2 methylation is feasible for individualized in prostate core biopsies before surgery. PITX2 was measured using a quantitative, methylation-specific real-time (PCR) in three cohorts: matched samples of neoplastic and non-neoplastic tissue from 24 PCa patients; a cohort of 300 patients with PCa after radical prostatectomy; and core biopsy specimens from 32 PCa patients and 31 patients with benign prostatic disease.

The researchers found that in patients with PCa, PITX2 methylation discriminated between neoplastic and non-neoplastic tissue (P < 0.001). PITX2 methylation correlated with clinicopathologic parameters in the second cohort, and PITX2 hypermethylation predicted an elevated risk of biochemical recurrence. Overall, 720 of 753 were applicable for analysis; PITX2 methylation was increased in tumor-positive biopsies and correlated with the International Society of Urological Pathology grade groups.

"This study indicates that the PITX2 methylation assay is feasible in prostate biopsies and might add valuable prognostic information for risk assessment in a presurgical diagnostic setting," the authors write.

Explore further: DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk

More information: Full Text (subscription or payment may be required)

Related Stories

DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk

December 8, 2016
Prostate-specific antigen (PSA) and other biomarkers are essential tools for diagnosing and monitoring prostate cancer. However, biomarkers to selectively identify patients with high risk of recurrence, those who might benefit ...

Age, obesity affect gene expression in symptomatic BPH

September 26, 2015
(HealthDay)—Age and obesity affect gene regulation in men with symptomatic benign prostatic hyperplasia, according to a study published in the October issue of The Journal of Urology.

Methylation of gene panel may help predict breast CA survival

November 29, 2016
(HealthDay)—Methylation of a gene panel is a strong predictor of survival outcomes in metastatic breast cancer (MBC), according to a study published online Nov. 21 in the Journal of Clinical Oncology.

New accurate epigenetic test could eliminate unnecessary repeat biopsies for prostate cancer

July 21, 2014
More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed. Therefore there is a need to develop diagnostic tests that will help avoid unnecessary ...

MRI feasible for predicting prostate CA in unselected sample

July 18, 2016
(HealthDay)—Prostate multiparametric magnetic resonance imaging (MRI) is feasible for predicting prostate cancer in an unselected sample of the general population, according to a study published in the August issue of The ...

Study affirms value of epigenetic test for markers of prostate cancer

May 28, 2014
A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many—if ...

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.